Last updated: June 12, 2026
Executive summary. The docket entry “Janssen Pharmaceuticals, Inc. v. Mylan Inc., 2:10-cv-06018” is too incomplete to produce a litigation summary that is accurate at the level required for patent and Paragraph IV risk analysis. No case caption metadata, asserted patent numbers, venue details, or operative settlement/claim-construction outcomes are provided, so a complete and dependable summary cannot be generated.
What is the litigation posture for Janssen Pharmaceuticals, Inc. v. Mylan Inc., 2:10-cv-06018?
Answer: Not determinable from the provided information.
Which patents were asserted in 2:10-cv-06018?
Answer: Not determinable from the provided information.
What is the Orange Book/Paragraph IV trigger for the asserted patents?
Answer: Not determinable from the provided information.
What claims were at issue (method of use, composition, formulation, or manufacturing)?
Answer: Not determinable from the provided information.
When was Janssen Pharmaceuticals, Inc. v. Mylan Inc., 2:10-cv-06018 filed and how did the case progress?
Answer: Not determinable from the provided information.
What procedural milestones occurred (complaint, answer, PTAB stays, Markman, summary judgment)?
Answer: Not determinable from the provided information.
Was there a settlement, consent judgment, or dismissal?
Answer: Not determinable from the provided information.
How does the case affect generic entry timing and Paragraph IV exposure?
Answer: Not determinable from the provided information.
Did any injunctions or non-infringement findings control launch?
Answer: Not determinable from the provided information.
What launch design risks remain for Mylan or other generics?
Answer: Not determinable from the provided information.
What patents protect the product(s) at issue and how strong is the estate?
Answer: Not determinable from the provided information.
What is the breakdown of claim types (formulation vs method-of-use vs process)?
Answer: Not determinable from the provided information.
What is the likely claim-construction impact on infringement?
Answer: Not determinable from the provided information.
What settlement terms typically flow from a Janssen v. Mylan Paragraph IV case, and were any reached here?
Answer: Not determinable from the provided information.
Were there “carve-outs” (indications, dosage forms, strengths) or agreed launch dates?
Answer: Not determinable from the provided information.
Did any party reserve rights for future patents or later FDA supplements?
Answer: Not determinable from the provided information.
What regulatory and FDA pathway factors influenced the litigation?
Answer: Not determinable from the provided information.
Was the generic seeking 505(b)(2), 505(j) ANDA, or another regulatory route?
Answer: Not determinable from the provided information.
What Orange Book listings and exclusivity periods were relevant?
Answer: Not determinable from the provided information.
Which companies and subsidiaries were involved, and what is the corporate/standing analysis?
Answer: Not determinable from the provided information.
Who held legal title and who was the technical party for ANDA submissions?
Answer: Not determinable from the provided information.
Key Takeaways
Answer: Not determinable from the provided information.
FAQs
- What patents were asserted in 2:10-cv-06018? Not determinable from the provided information.
- Was there a Markman ruling affecting infringement or validity? Not determinable from the provided information.
- Did the case end in settlement, injunction, or dismissal? Not determinable from the provided information.
- How did the outcome impact Mylan’s generic launch dates? Not determinable from the provided information.
- Which FDA Orange Book listings were tied to the Paragraph IV notices? Not determinable from the provided information.
References
No sources cited.
